Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Form 144 filed to report a proposed sale of 2,444 shares of Common Stock on 06/08/2026 via a stock option exercise through the issuer for cash. The filing lists prior dispositions in the past three months: 2,309 on 05/11/2026, 2,427 on 04/10/2026, and 2,319 on 03/10/2026.
Doximity, Inc. interim PFO and PAO Siddharth Sitaram reported a tax-withholding disposition of 1,246 shares of Class A Common Stock at $18.01 per share. The shares were withheld by the company to satisfy tax obligations on vesting RSUs and were not a discretionary trade. Sitaram directly owns 88,150 shares after this transaction.
Doximity, Inc. Chief Executive Officer Jeffrey Tangney reported compensation-related equity activity. He received a grant of 322,614 shares of Class A Common Stock for $0.00 per share, tied to performance-based restricted stock units. On the same date, 14,964 shares were withheld at $18.01 per share to cover tax obligations on previously vested restricted stock units. After these transactions, he directly holds 2,540,460 Class A shares.
Doximity, Inc. describes its physician-focused technology platform, AI tools, and key risks in its Annual Report for the year ended March 31, 2026. The company reports over 3 million registered members, representing more than 85% of approximately 1 million U.S. physicians, plus large portions of nurse practitioners, physician assistants, and medical students.
Doximity monetizes this network through subscription-based Marketing, Hiring, and Workflow Solutions sold mainly to pharmaceutical companies and health systems, and highlights rapid adoption of its Clinical AI Suite, including Ask, Scribe, and Dialer, across more than 140 U.S. health systems. It notes revenue growth of 13% in fiscal 2026 versus 20% in 2025, headcount of 880 full-time equivalent employees, a dual class share structure, customer concentration risks, growing competition in healthcare AI and telehealth, and extensive regulatory and data-privacy obligations.
Doximity, Inc. reporting persons filed an amendment to their Schedule 13G/A disclosing beneficial ownership stakes in the company's capital structure.
The filing shows that Jeffrey Tangney and Claudia Schweikert (and related trusts) collectively beneficially own large positions: Tangney and Schweikert each report 55,459,800 shares (treated as 29.9% of Class A on a conversion basis). The filing states the conversion and voting mechanics for Class B shares and provides outstanding share counts as of March 31, 2026.
Doximity, Inc. interim PFO and PAO Siddharth Sitaram reported routine equity transactions involving Class A and Class B shares. He exercised a stock option covering 5,000 shares of Class B Common Stock at a $4.12 exercise price, which converted into 5,000 shares of Class A Common Stock. On the same date, he sold 2,309 shares of Class A Common Stock at $25.77 per share in an automatic Rule 10b5-1 sell-to-cover transaction to satisfy tax withholding obligations. Following these transactions, he directly held 89,396 shares of Class A Common Stock.
Doximity, Inc. reported fiscal year 2026 revenue of $644.9 million, up 13% from $570.4 million, with adjusted EBITDA rising to $357.8 million and free cash flow to $317.5 million, both up 14–19% year-over-year.
GAAP net income for the year declined to $196.1 million from $223.2 million as margins narrowed, though non-GAAP net income improved to $302.7 million. In Q4, revenue grew 5% to $145.4 million, while net income fell to $19.1 million, reflecting higher operating expenses and stock-based compensation. The company highlighted strong engagement, with over 800,000 active prescribers using workflow tools in Q4 and broad adoption of its clinical AI features.
For fiscal 2027, Doximity guides to revenue of $664–$676 million and adjusted EBITDA of $323–$335 million. The company also appointed Matthew Sonefeldt as Chief Financial Officer and Steven L. Zatz, M.D. as President, each with base salary of $400,000 and multi‑year RSU packages tied to time-based and performance-based vesting.
Reporting person Siddharth submitted a notice of proposed sale of 2,309 shares of Common Stock of DOCS by means described as a Stock Option Exercise to be effected on 05/11/2026. The filing also lists prior sales of 2,427 shares on 04/10/2026 and 2,319 shares on 03/10/2026.
Doximity, Inc. director Kira Scherer Wampler reported an open-market sale and related equity conversions. On May 7, 2026, she sold 9,000 shares of Class A Common Stock at $26.06 per share and held 19,839 Class A shares afterward.
On the same date, she exercised and converted derivative positions involving 9,000 shares of Class B Common Stock into Class A Common Stock and partially exercised a stock option covering 9,000 underlying Class B shares at a $1.54 exercise price. A footnote states the sale occurred automatically under a Rule 10b5-1 trading plan adopted on November 12, 2024, indicating the transaction was pre‑planned rather than discretionary.